Ceftazidime and avibactam (Avycaz) approved for hospital-acquired pneumonias
www.pulmccm.org
The FDA approved a new indication for the antibiotic combination ceftazidime and avibactam (marketed as Avycaz), for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults. The drug was approved originally in 2015 for complicated intra-abdominal infections (in combination with metronidazole) and got another indication in 2017 for complicated urinary tract infections and pyelonephritis.
Ceftazidime and avibactam (Avycaz) approved for hospital-acquired pneumonias
Ceftazidime and avibactam (Avycaz) approved…
Ceftazidime and avibactam (Avycaz) approved for hospital-acquired pneumonias
The FDA approved a new indication for the antibiotic combination ceftazidime and avibactam (marketed as Avycaz), for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia in adults. The drug was approved originally in 2015 for complicated intra-abdominal infections (in combination with metronidazole) and got another indication in 2017 for complicated urinary tract infections and pyelonephritis.